VRPX vs PFE vs JPM vs MRK vs ABBV vs KO

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 8x trailing P/E (22. 4x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 8x versus AbbVie Inc. at 93. 9x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 84x versus The Coca-Cola Company's 2. 20x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +126. 7%, compared to -100. 0% for Virpax Pharmaceuticals, Inc. (VRPX). Over 10 years, the gap is even starker: JPM returned +492. 1% versus VRPX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Virpax Pharmaceuticals, Inc.

(VRPX) is the lower-risk stock at -0. 45β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately -310% more volatile than VRPX relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -446. 7% for Virpax Pharmaceuticals, Inc.. Over a 3-year CAGR, KO leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for Virpax Pharmaceuticals, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus 0. 0% for VRPX. At the gross margin level — before operating expenses — MRK leads at 72. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 84x versus The Coca-Cola Company's 2. 20x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 8x forward P/E versus 24. 6x for The Coca-Cola Company — 15. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 15. 5% to $256. 92.

In this comparison, PFE (6.

6% yield), ABBV (3. 0% yield), MRK (2. 8% yield), KO (2. 5% yield), JPM (1. 8% yield) pay a dividend. VRPX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +115. 4% 10Y return). Both have compounded well over 10 years (KO: +115. 4%, JPM: +492. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VRPX (Healthcare) and PFE (Healthcare) and JPM (Financial Services) and MRK (Healthcare) and ABBV (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VRPX is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock; JPM is a large-cap deep-value stock; MRK is a large-cap deep-value stock; ABBV is a large-cap quality compounder stock; KO is a large-cap quality compounder stock. PFE, JPM, MRK, ABBV, KO pay a dividend while VRPX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.